Brief: Northwest Biotherapeuticsannounces operations updates
02/05/2016 22:00
May 2 (Reuters) - Northwest Biotherapeutics Inc NWBO.O
* Nw bio announces operations updates
* Reached agreement with three parties, in regard to three
combination treatments, for three cancers in three phase ii
trials
* Phase iii trial of DCVAX-l for GBM brain cancer subject to
partial clinical hold on screening of additional patient
candidates
* Reached agreement with initial members of sab, including
"leading experts" in immunotherapy, oncology from both us,
europe
* Company's phase iii trial of DCVAX-l for GBM brain cancer
is ongoing
* Company is in ongoing dialog with regulators, and
providing further information about DCVAX-l trial
* Establishing a scientific advisory board
Source text for Eikon: ID:nPnbqnJTda
Further company coverage: NWBO.O
Recent news on Northwest Biotherapeutics
See all newsBrief: Northwest Biotherapeutics And The UK National Health Service Blood And Transplant Announce Collaboration To Support Dcvax®-L Production
Brief: Northwest Biotherapeutics Provides Update On Final Preparations For Marketing Authorization Application
Brief: Northwest Biotherapeutics Provides Update On Near Term Plans For Submission Of Marketing Authorization Application
Brief: Northwest Biotherapeutics And Advent Bioservices Announce Receipt Of License For Commercial Manufacturing At Sawston, U.K. Facility
Brief: Northwest Biotherapeutics Announces That It Has No Banking Relationship With SVB